BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18792871)

  • 1. Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?
    Major-Pedersen A; Ihlemann N; Hermann TS; Christiansen B; Kveiborg B; Dominguez H; Nielsen D; Rask-Madsen C; Svendsen OL; Køber L; Torp-Pedersen C
    Horm Metab Res; 2008 Sep; 40(9):607-13. PubMed ID: 18792871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
    Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
    Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
    Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
    Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
    Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
    Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
    Mine T; Miura K; Kitahara Y; Okano A; Kawamori R
    Biol Pharm Bull; 2002 Nov; 25(11):1412-6. PubMed ID: 12419950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
    Hirose T; Mizuno R; Yoshimoto T
    Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.
    Kato T; Inoue T; Node K
    Cardiovasc Diabetol; 2010 Mar; 9():12. PubMed ID: 20334663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
    Hazama Y; Matsuhisa M; Ohtoshi K; Gorogawa S; Kato K; Kawamori D; Yoshiuchi K; Nakamura Y; Shiraiwa T; Kaneto H; Yamasaki Y; Hori M
    Diabetes Res Clin Pract; 2006 Mar; 71(3):251-5. PubMed ID: 16214255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of nateglinide in impaired glucose tolerance subjects].
    Hirose T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
    [No Abstract]   [Full Text] [Related]  

  • 10. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
    Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
    Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
    Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
    Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nateglinide and mitiglinide].
    Odawara M
    Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
    Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
    Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of nateglinide in the management of patients with type 2 diabetes.
    Tentolouris N; Voulgari C; Katsilambros N
    Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
    Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
    González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
    J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
    Miura K; Kitahara Y; Yamagishi S
    Horm Metab Res; 2010 Sep; 42(10):731-5. PubMed ID: 20625970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
    Ikenoue T; Kondo N
    Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.